BioSpace News Archive

NanoMosaic was invited by the organizers of the American Association of Cancer Research to formally participate in its prestigious annual meeting with two poster presentations focused on central issues in furthering the field of oncology treatment and research

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that Mr. Gilead Raday, RedHill’s Chief Operating Officer, will present the Company’s ongoing Phase 2/3 development programs with opaganib 1 and RHB-107 2 for COVID-19 at the Sachs Digital Novel Coronavirus Investment Forum, taking place July 7-9, 2020.

KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020

Therapix Biosciences Ltd. (Nasdaq: TRPX) (the “Company” or “Therapix”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Injunction from Israeli Court. Notice of Delisting On June 30, 2020 , Therapix Biosci

Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a peer-reviewed article published in Clinical Cancer Research (Clin Cancer Res June 30 2020 DOI:10.1158/1078-0432.CCR-19-4092) reported findings that Moleculin’s STAT3 inhibitor,

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2020, at 8 a.m. EDT on Thursday, July 30, 2020. Analysts and investors can participate in the conference call b

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, announced that the company has entered into a collaborative research agreement with Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science.

Mentice AB announced the appointment of Thanos Karras as the company’s new General Manager for Americas.